Vitruvias recalls a lot of thyroid tablets found to be superpotent, in a Class I action

Vitruvias Therapeutics has recalled a batch of its Thyroid Tablets after testing found the tablets to be superpotent — carrying more active hormone than the label declares [s1]. The Food and Drug Administration classified the recall, numbered D-0866-2026, as Class I, its most serious category, reserved for products the agency judges could cause serious injury or death [s1]. The action began on 21 August 2026 and the FDA posted its enforcement report on 23 September 2026 [s1].

The recall covers a single lot — number 504950, with an expiry of 30 September 2026 — amounting to 1,955 bottles distributed across the United States [s1]. The affected product is Thyroid Tablets USP, 1/2 Grain (30 mg), a prescription product distributed by Vitruvias Therapeutics of Auburn, Alabama, under national drug code 69680-166-00 [s1]. The FDA's drug directory lists the same product as a 30 mg thyroid tablet from Vitruvias, first marketed on 22 November 2024 [s2].

What the tablets contain

This is not a single-ingredient levothyroxine pill. Each tablet is labelled to contain two thyroid hormones — levothyroxine (T4) at 19 micrograms and liothyronine (T3) at 4.5 micrograms — the combination characteristic of desiccated- and combination-thyroid products [s1]. A "superpotent" finding means the batch was measured to hold more of that active content than stated [s1]. The enforcement report gives the recall reason simply as "Superpotent Drug" and does not quantify by how much [s1].

Thyroid hormone is prescribed in micrograms and titrated carefully, because the gap between a therapeutic dose and an excessive one is narrow. A tablet that delivers more hormone than intended, taken daily over weeks, pushes a patient toward overtreatment — the territory of a suppressed thyroid-stimulating hormone and the symptoms that accompany too much thyroid hormone. The recall classification reflects that the agency regards the potential for harm here as serious rather than theoretical [s1].

Why potency errors matter here

Thyroid replacement is one of the most widely taken long-term prescriptions, and patients generally feel stable on a fixed daily dose. That stability is also what makes a potency error easy to miss: there is no immediate signal that a tablet is stronger than it should be, and any effect builds gradually. Combination T4/T3 products add a further wrinkle, because T3 is the faster-acting, more potent of the two hormones, so an across-the-board potency excess is not benign.

The scope here is narrow — one lot, fewer than two thousand bottles, each holding 100 tablets, already near its labelled expiry of 30 September 2026 [s1]. That limits how many people are exposed, but it does not change the individual risk for someone holding an affected bottle. The product is prescription-only and was first marketed in late 2024, so affected bottles have been in circulation for less than two years [s1][s2].

Potency failures cut both ways across the drug supply — recalls for subpotent thyroid tablets, which would under-treat, appear alongside superpotent ones — and the testing that catches them is a routine part of manufacturing oversight. What distinguishes this action is the direction of the error and the Class I rating the FDA attached to it, signalling that an excess of thyroid hormone in a daily medicine is not something the agency treats as minor [s1].

How to read it

A Class I designation describes the FDA's assessment of potential severity, not a count of injuries; the enforcement report documents a defect and a recall, not reported harms [s1]. The practical value of the notice is identification: the lot number, the expiry date and the national drug code are the details that let a patient or pharmacist tell whether a bottle on hand is affected [s1][s2]. Because the recall is firm-initiated and voluntary, it proceeds through the supply chain and pharmacies rather than as a mandatory seizure [s1].

What to watch

Whether the recall stays confined to this lot, and whether the FDA adds any findings as the action continues, will show in future updates to the enforcement record [s1]. Patients who take Vitruvias Thyroid Tablets can check the lot number against the notice and consult their pharmacist or prescriber rather than stopping the medicine on their own.

This article describes a drug-safety action and is not medical advice. Do not stop thyroid medication without medical guidance — abrupt discontinuation carries its own risks. Seek medical advice if you experience signs of thyroid excess such as a racing or irregular heartbeat, chest pain, tremor, unexplained weight loss, heat intolerance or anxiety.

Sources

• Enforcement Report D-0866-2026: Thyroid Tablets USP 1/2 Grain (30 mg), Class I recall (superpotent drug) — U.S. Food and Drug Administration, report posted 23 September 2026
• NDC Directory: Thyroid (NDC 69680-166), Vitruvias Therapeutics — product record — U.S. Food and Drug Administration